A3（人T淋巴細胞白血病細胞）
CBP60703
詢 價
索取STR
產品描述
產品數據庫
| I. General information | |
| Synonyms: | A3 |
| Background: | The A3 subclone was derived from a Jurkat cell line obtained from the laboratory of Gerald Crabtree at Stanford University. |
| Species: | Homo sapiens, human |
| Disease: | acute T cell leukemia |
| Gender: | male |
| Morphology: | lymphoblast |
| Growth Mode: | suspension |
| DNA Profile: | Amelogenin: X,Y CSF1PO: 11,12 D13S317: 8,11 D16S539: 11 D5S818: 9 D7S820: 8,10 THO1: 6,9.3 TPOX: 8,10 vWA: 17,18 Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640 +10%FBS A3完全培養(yǎng)基，# CBP60703M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Comments: | The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis.The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis.Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks.Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD. For more information, please contact us (4008-750-250). |
